|BrainStorm Issues 2018 Letter to Shareholders|
Dear Valued Shareholder,
This past year was an extraordinary success for BrainStorm Cell Therapeutics from a research and development, clinical, financial and corporate perspective. I appreciate the many accomplishments of our employees and the dedicated support we have received from investors, as we execute on our goal of bringing critical treatments to those suffering from neurodegenerative diseases.
I want to acknowledge the efforts of the six key centers enrolling patients in the Company’s NurOwn® Phase 3 clinical trial for the treatment of amyotrophic lateral sclerosis (ALS):
On the research and development front, the U.S. Food and Drug Administration recently approved the Company’s NurOwn investigational new drug application for a Phase 2 study in progressive Multiple Sclerosis (MS). We plan to initiate a study in this patient population in the first quarter of 2019 and will provide additional details regarding the trial design and participating centers. Expanding our clinical trial program into progressive MS is an important achievement in establishing NurOwn as a platform technology, and furthermore, we are conducting pre-clinical research in other neurodegenerative diseases, and plan to announce additional potential indications in 2019.
This year we also expanded our NurOwn manufacturing capabilities by transferring operations to the
In 2018, we focused on strengthening our financial position; we received
We expanded our patent portfolio by obtaining additional
Lastly, we strengthened our executive team and board of directors. We added three senior members to our executive team:
Looking ahead to 2019, we remain focused on completing enrolment in the ALS phase 3 study and initiating the progressive MS phase 2 studies are our highest priorities. We will continue to lead the development of cellular therapeutics in neurodegenerative disease, seek additional opportunities to expand our pipeline to address unmet need and continue to enhance our manufacturing capabilities and infrastructure.
I want to personally thank you for your continued support.